Zynerba Pharmaceuticals Inc (ZYNE) Receives Consensus Rating of “Hold” from Analysts

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) has earned a consensus rating of “Hold” from the twelve brokerages that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and three have issued a buy rating on the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $14.00.

Several equities analysts have commented on the stock. Zacks Investment Research downgraded shares of Zynerba Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, November 18th. Roth Capital set a $15.00 price target on shares of Zynerba Pharmaceuticals and gave the company a “buy” rating in a research note on Sunday, October 1st. Cantor Fitzgerald set a $17.00 price target on shares of Zynerba Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, January 3rd. Canaccord Genuity set a $18.00 price target on shares of Zynerba Pharmaceuticals and gave the company a “buy” rating in a research note on Monday, December 4th. Finally, Piper Jaffray Companies upped their price target on shares of Zynerba Pharmaceuticals from $16.00 to $20.00 in a research note on Tuesday, November 14th.

Shares of Zynerba Pharmaceuticals (ZYNE) traded down $0.07 on Friday, reaching $11.43. 229,800 shares of the company’s stock were exchanged, compared to its average volume of 363,383. Zynerba Pharmaceuticals has a 1 year low of $5.42 and a 1 year high of $25.95. The company has a market capitalization of $155.73 and a price-to-earnings ratio of -4.41.

Zynerba Pharmaceuticals (NASDAQ:ZYNE) last announced its quarterly earnings data on Tuesday, November 14th. The company reported ($0.63) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.58) by ($0.05). During the same period last year, the company earned ($0.67) EPS. analysts forecast that Zynerba Pharmaceuticals will post -2.49 earnings per share for the current fiscal year.

In other Zynerba Pharmaceuticals news, major shareholder Michael Rapp purchased 15,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 2nd. The shares were acquired at an average cost of $12.99 per share, for a total transaction of $194,850.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 9.91% of the company’s stock.

A number of institutional investors have recently made changes to their positions in the business. Nationwide Fund Advisors acquired a new stake in shares of Zynerba Pharmaceuticals during the 2nd quarter worth approximately $110,000. Zeke Capital Advisors LLC bought a new stake in shares of Zynerba Pharmaceuticals during the 3rd quarter worth $114,000. The Manufacturers Life Insurance Company bought a new stake in shares of Zynerba Pharmaceuticals during the 2nd quarter worth $158,000. Cowen Inc. bought a new stake in shares of Zynerba Pharmaceuticals during the 3rd quarter worth $167,000. Finally, New York State Common Retirement Fund bought a new stake in shares of Zynerba Pharmaceuticals during the 2nd quarter worth $207,000. Hedge funds and other institutional investors own 26.71% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Zynerba Pharmaceuticals Inc (ZYNE) Receives Consensus Rating of “Hold” from Analysts” was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another website, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2018/01/19/zynerba-pharmaceuticals-inc-zyne-receives-consensus-rating-of-hold-from-analysts.html.

Zynerba Pharmaceuticals Company Profile

Zynerba Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs. Its development pipeline includes two product candidates: ZYN002 and ZYN001. ZYN002 is a synthetic cannabidiol (CBD), which is a non-psychoactive cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system.

Analyst Recommendations for Zynerba Pharmaceuticals (NASDAQ:ZYNE)

Receive News & Ratings for Zynerba Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynerba Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply